Research/art/teacher profile of a person
Name and surname:
doc. PharmDr. Andrea Gažová, PhD.
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Gažová
I.2 - Name
Andrea
I.3 - Degrees
Doc., PharmD., Phd.
I.4 - Year of birth
1980
I.5 - Name of the workplace
Comenius University in Bratislava, Faculty of Medicine, Institute of Pharmacology and Clinical Pharmacology
I.6 - Address of the workplace
Špitálska 24, 813 72 Bratislava
I.7 - Position
university teacher - Ass.professor
I.8 - E-mail address
andrea.gazova@fmed.uniba.sk
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/3152
I.10 - Name of the study field in which a person works at the university
clinical pharmacology
I.11 - ORCID iD
0000-0002-4515-5693

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Pharmacy
II.b - Year
2004
II.c - Study field and programme
pharmacy
II.2 - Second degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Pharmacy
II.b - Year
2004
II.c - Study field and programme
pharmacy
II.3 - Third degree of higher education
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Medicine
II.b - Year
2009
II.c - Study field and programme
clinical pharmacology
II.4 - Associate professor
II.a - Name of the university or institution
Comenius University in Bratislava, Faculty of Medicine
II.b - Year
2020
II.c - Study field and programme
clinical pharmacology
II.5 - Professor
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
assistant, assistant professor, docent Comenius University in Bratislava, Faculty of Medicine 2004 -

IV. - Development of pedagogical, professional, language, digital and other skills

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.1.a - Name of the profile course V.1.b - Study programme V.1.c - Degree V.1.d - Field of study
clinical pharmacology general medicine I.+II. general medicine
clinical pharmacology dentistry I.+II. dentistry
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.2.a - Name of the study programme V.2.b - Degree V.2.c - Field of study
clinical pharmacology III. general medicine
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.2 - Number of defended theses
V.5 - Overview of other courses taught in the current academic year according to study programmes
V.5.a - Name of the course V.5.b - Study programme V.5.c - Degree V.5.d - Field of study
Application of medical devices in patient therapy general medicine II.+III. general medicine

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
351
VI.1.b - Over the last six years
156
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
52
VI.1.b - Over the last six years
32
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
403
VI.1.b - Over the last six years
372
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
398
VI.1.b - Over the last six years
270
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
3
VI.1.b - Over the last six years
2
VI.2 - The most significant research/artistic/other outputs
1

ACB04 Gažová, Andrea [UKOLFFAU] (71% [3,88 AH]) - Kyselovič, Ján [UKOLF5IK] (29% [1,59 AH]): Princípy receptúrnej propedeutiky. - 1. vyd. - Bratislava : Berlina, 2020. - 114 s. [5,47 AH]

ISBN 978-80-972674-8-3

In this university textbook, we describe the legislative requirements for correctly writing a prescription form under eHEALTH conditions.

2

ADC03 Křenek, Peter [UKOFAFT] (12%) - Kmecová, Jana (11%) - Kučerová, Dana (11%) - Bajuszová, Zuzana (11%) - Musil, Peter (11%) - Gažová, Andrea [UKOLFFAU] (11%) - Ochodnický, Peter (11%) - Klimas, Ján [UKOFAFT] (11%) - Kyselovič, Ján [UKOLF5IK] (11%):Isoproterenol-induced heart failure in the rat is associated with nitric oxide-dependent functional alterations of cardiac function

Lit. 35 zázn.

In: European Journal of Heart Failure. - Vol. 11, No. 2 (2009), s. 140-146. - ISSN (print) 1388-9842

Registrované v: wos

Indikátor časopisu:

IF (JCR) 2009=3,706

POZNÁMKA:

Vyšiel aj ako abstrakt v slovenčine - Kardiológia/Cardiology. - Roč. 18, Suppl. 1 (2009), s. 46S

Ohlasy (67):

The most cited publication in which we describe the simulation of heart failure, hypertrophy, administration of isoprenaline (IZO) and monitoring of NOS expression, development of fibrosis or other possible manifestations of heart damage. IZO-induced cardiac hypertrophy is a reliable, reproducible and well-characterized model of cardiac hypertrophy associated with arrhythmias, myocyte loss and progressive fibrosis.

The aim of our experimental work with IZO was to describe the effects of NO on the regulation of heart rhythm and myocardium, contractility and expression of NOS and their allosteric regulators in IZO-induced heart failure. In this study, we present new observations demonstrating that NOS capacity was increased in IZO-induced heart failure and was associated with altered NO-mediated cardiac function, specifically altered heart rate regulation and loss of the positive inotropic effect of NO in left ventricular myocytes.

3

ADC09 Gažová, Andrea [KAUT] [UKOLFFAU] (30%) - Samáková, Adriana [UKOFAFT] (10%) - Laczo, Eugen [UKOTVKLA] (10%) - Hamar, Dušan [UKOTVKKA] (10%) - Polakovičová, Mája [UKOFAFCH] (5%) - Juríková, Miroslava [UKOLFUHE] (5%) - Kyselovič, Ján [UKOLF5IK] (30%): Clinical utility of miRNA-1, miRNA-29g and miRNA-133s plasma levels in prostate cancer patients with high-intensity training after androgen-deprivation therapy

Lit.: 36 zázn.

In: Physiological Research. - Roč. 68, č. Supplement 2 (2019), s. S139-S147. - ISSN (print) 0862-8408

Registrované v: wos

Registrované v: scopus

Indikátor časopisu:

IF (JCR) 2018=1,701

It is possible that the issue of early diagnosis of pathological process (oncological or other mechanism) can be solved by research in the field of microRNAs and their evaluation represents a promising target for microRNA-based diagnostics. Currently, there is a lack of methods for early detection and screening tests. Recent clinical and experimental studies have shown that microRNAs have different expression profiles in normal and cancer cells, which are tissue-specific. We hypothesized that in patients on ADT, strength training would increase muscle strength, improve body composition and physical function in older men with PC. We showed not only a significant average increase (+20.51%, p = 0.006) and maximum (+22.55%, p = 0.040) strength, muscle strength (+17%), an increase in body weight by 4.65%, but also changes in plasma levels of microRNAs. Each microRNA can interact with different cells in the cascade pathway, and therefore changes in the expression of several microRNAs can affect the deregulation of multiple cellular processes contributing to the complexity of not only oncological but also other pathological or regenerative processes. In our study, we found significantly lower levels of microRNA-1 expression in the control, non-influenced group trained with PC, while the expression of microRNA-1 changed in the experimental group. In addition, we also noted an altered expression of microRNA-29b.

4

ADC11 Samáková, Adriana [UKOFAFT] (20%) - Gažová, Andrea [KAUT] [UKOLFFAU] (20%) - Sabová, Nikola [UKOFAFT] (15%) - Valášková, Simona [UKOFAFT] (15%) - Juríková, Miroslava [UKOLFUHE] (10%) - Kyselovič, Ján [UKOLF5IK] (20%): The pi3k/Akt pathway is associated with angiogenesis, oxidative stress and survival of mesenchymal stem cells in pathophysiologic condition in ischemia

Lit.: 28 zázn.

In: Physiological Research. - Roč. 68, č. Supplement 2 (2019), s. S131-S138. - ISSN (print) 0862-8408

Registrované v: wos

Registrované v: scopus

Indikátor časopisu:

IF (JCR) 2018=1,701

              One of the promising options for the treatment of patients with ischemic diseases is cell therapy, where mesenchymal stem cells are primarily used, which, thanks to their multifactorial action, contribute to the significant progress of therapy for these patients. Considerable attention is paid to the ability of mesenchymal stem cells to differentiate and transdifferentiate into other cell types, especially cardiomyocytes, however, numerous laboratory studies, experiments and clinical observations have shown that bone marrow cells do not directly differentiate into new cardiomyocytes. Instead, it appears that these cells process signals and control the response of surrounding damaged cells, thereby regulating healing. Therefore, understanding the basic characteristics and modalities of secretion of cytoprotective molecules is essential for the future clinical use of MSC cells and the application of these findings to real cardiac regenerative therapies. In the article "The pi3k/Akt Pathway Is Associated With Angiogenesis, Oxidative Stress and Survival of Mesenchymal Stem Cells in Pathophysiologic Condition in Ischemia" (Samakova et al. 2019b), we describe possible signaling cascades that are activated or inactivated by statin application, and these assumptions have already been partially clinically verified by our team. The immediate paracrine effect of stem cells in the ischemic area is the release of cytoprotective molecules that support the survival of ischemic cells. The most studied events in which the aforementioned processes occur are myocardial protection and neovascularization, where paracrine factors affect damaged cells.

5

ADM07 Gažová, Andrea [KAUT] [UKOLFFAU] (35%) - Valášková, Simona [UKOFAFT] (10%) - Žufková, Viera [UKOFAJ] (10%) - Castejon, Ana M. (10%) - Kyselovič, Ján [UKOLF5IK] (35%): Clinical study of effectiveness and safety of CELcomplex containing Cucurbita Pepo Seed extract and Flax and Casuarina on stress urinary incontinence in women

In: Journal of Traditional and Complementary Medicine [elektronický dokument]. - Roč. 9, č. 2 (2019), s. 138-142 [online]. - ISSN (online) 2225-4110

URL: https://reader.elsevier.com/reader/sd/E8150D456AAB5AB406B78573CEC61DFA9B9184AD3803072C10DA48517AE58ABBD090ABAC1A0AD422E3728076A9DE3E0D

Registrované v: scopus

Ohlasy (2):

               Female incontinence is a clinically serious problem not only from a pathological, but mainly from a socio-psychological point of view. Despite some progress, pharmacological treatment of stress incontinence is still problematic and brings with it undesirable effects, many times exceeding the benefit of the given treatment. A certain possibility is the use of phytotherapy with extracts from Cucurbita pepo seeds, which represents an interesting potential for the treatment of this disease. In a multicenter, open clinical study of the nature of biomedical research, we investigated the potential positive effect of Incovenal® comfort, which contains extracts from Cucurbita pepo in a unique CEL complex, on a relatively large group of 156 patients, 86 of whom suffered from stress incontinence of the first or second degree. After 12 weeks of therapy with a combination of Cucurbita pepo, Equisetum arvense (Field Horsetail), Linum usitatissimun (Flax), vitamins D and C, we demonstrated a significant reduction in incontinence episodes during the day, a reduction in the urge to urinate during the day and at night.

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Caco-2 monolayer as a model of the intestinal barrier: Permeability of Magnesium salts

N Chomanicova, A Adamickova, S Valaskova, A Gazova, J Kyselovic

Adult Stem Cells: Methods and Protocols, 301-306

2

Isolation and Characterization of Human Dental Pulp Stem Cells Derived from Dental Pulp of Permanent Teeth

A Adamickova, N Chomanicova, M Adamicka, S Valaskova, A Gazova, ...

Adult Stem Cells: Methods and Protocols, 49-57

3

Effects of Ibuprofen and Diclofenac Pre-Treatment on Viability and Apoptosis Processes in Human Dental Pulp Stem Cells

A Adamičková, J Kyselovic, M Adamička, N Chomaničová, S Valášková, A Gazova,

Medicina 60 (5), 787

4

COMPARISON OF GENE EXPRESSION OF EPICARDIAL ADIPOSE TISSUE AND LEFT VENTRICULAR MYOCARDIUM IN END-STAGE HEART FAILURE

Autori

Jan Kyselovic, Jana Mlynarova, Peter Musil, Michal Hulman, Ivo Gasparovic, Andrea Gazova

Journal of Hypertension 41 (Suppl 3), e232-e233

5

A new caco-2 cell model of in vitro intestinal barrier: application for the evaluation of magnesium salts absorption

Autori

Ján Kyselovič, Nikola Chomanicova, Adriana Adamičková, Simona Valášková, Barbara Šalingová, Andrea Gažová

Physiological research 70 (Suppl 1), S31

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

[o1] 2018 ~ Komoda, H. - Shiraki, A. - Oyama, J.I. - Nishikido, T. - Node, K.: Azelnidipine inhibits the differentiation and activation of THP-1 macrophages through the L-type calcium channel. In: Journal of Atherosclerosis and Thrombosis,vol. 25, no. 8, 2018, s. 690-697 -- SCI ; SCOPUS

2

[o1] 2021 ~ Bernak-Oliveira, A. - Guizoni, D.M. - Chiavegatto, S. - Davel, A.P. - Rossoni, L.V.: Life Sciences, vol. 285, 2021, art. no. 119939 -- SCI ; SCOPUS

3

[o1] 2013 ~ Arechederra, M. - Carmona, R. - González-Nunez, M. - Gutiérrez-Uzquiza, T. - Bragado, P. - Cruz-González, I. - Cano, E. - Guerrero, C. - Sánchez, A. - López-Novoa, J.M. - Schneider, M.D. - Maina, F. - Munoz-Chápuli, R. - Porras,A.: Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1832, no. 12, 2013, s. 2204-2215 -- SCI ; SCOPUS

4

[o1] 2016 ~ Ozcan, G. - Sahin, E.A. - Demirel Yilmaz, E.: Turkiye Klinikleri Cardiovascular Sciences, vol. 28, no. 3, 2016, s. 99-117 -- SCOPUS

5

[n1] 2022 zz ~ Wang, Y. - Wang, D. - Wu, C. - Wang, B. - He, S. - Wang, H. - Liang, G. - Zhang, Y.: Theranostics, vol. 12, no. 17, 2022, s. 7237-7249 -- SCI ; SCOPUS

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years
1

2018-2020 KEGA 038UK-4/2018 Integration of model situations into the teaching of general pharmacology with the implementation of the iSTAN simulator into the pharmacokinetic and pharmacodynamic characteristics of drugs

2

2021-2023 KEGA 058UK-4/2022 Application of pharmacology teaching to solving clinical cases in internal medicine

3

2021-2025 COST CA20121 Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases

4

2022-2026 COST CA21151 Generation of human induced pluripotent stem cells from haplo-selected cord blood samples (haplo-ips)

5

2024-2028 APVV-23-0557 Signaling pathways of miRNA and ICD proteins in the human ischemic heart

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VII.a - Activity, position VII.b - Name of the institution, board VII.c - Duration
member of the editorial board PharmaNews lasts
member of the editorial board Medicus lasts
member of the editorial board Physiologie Reserch lasts

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

IX. - Other relevant facts

Date of last update
2025-01-30